The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer

Gemcitabine (GEM) resistance is a critical issue for pancreatic cancer treatment. The involvement of epigenetic modification in GEM resistance is still unclear. We established a GEM-resistant subline PANC-1-R from the parental PANC-1 pancreatic cancer cells and found the elevation of various chromat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Mei-Ren, Hsu, Ming-Chuan, Luo, Chi-Wen, Chen, Li-Tzong, Shan, Yan-Shen, Hung, Wen-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308641/
https://www.ncbi.nlm.nih.gov/pubmed/27531902
http://dx.doi.org/10.18632/oncotarget.11256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308641/
https://www.ncbi.nlm.nih.gov/pubmed/27531902
http://dx.doi.org/10.18632/oncotarget.11256

Ejemplares similares